ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

ClinicalTrials.gov ID: NCT03056755

Public ClinicalTrials.gov record NCT03056755. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments

Study identification

NCT ID
NCT03056755
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
383 participants

Conditions and interventions

Conditions

Interventions

  • Alpelisib Drug
  • Fulvestrant Drug
  • Goserelin Drug
  • Letrozole Drug
  • Leuprolide Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 28, 2017
Primary completion
Jun 13, 2021
Completion
Nov 11, 2024
Last update posted
Jan 12, 2026

2017 – 2024

United States locations

U.S. sites
25
U.S. states
16
U.S. cities
23
Facility City State ZIP Site status
Banner MD Anderson Cancer Center Gilbert Arizona 85234
Mayo Clinic Arizona Phoenix Arizona 85054
Kaiser Permanente Medical Group Anaheim California 92807
Beverly Hills Cancer Center Beverly Hills California 90211
University of Calif Irvine Med Cntr Irvine California 92660
Kaiser Permanent Southern Californi San Diego California 92120
UCSF San Francisco California 94115
Yale University Yale Cancer Center New Haven Connecticut 06511
Advent Health Cancer Institute Orlando Florida 32804
University of Kansas Cancer Center Kansas City Kansas 66205
University of Louisville James Graham Brown Cancer Center Louisville Kentucky 40202
Mercy Medical Center Baltimore Maryland 21202
Greater Baltimore Med Center Cancer Center Baltimore Maryland 21204
Massachusetts General Hospital Boston Massachusetts 02114
Lahey Clinic Burlington Massachusetts 01805
Josephine Ford Cancer Center Detroit Michigan 48202
St Vincent Frontier Cancer Center Billings Montana 59102
New Mexico Cancer Care Alliance Albuquerque New Mexico 87106
Memorial Sloane Ketterin Cancer Ctr New York New York 10065
Uni Hosp of Cleveland Cancer Center Cleveland Ohio 44106
Texas Oncology Dallas Texas 75246
Cancer Care Centers of South Texas HOAST San Antonio Texas 78229
UT Health San Antonio San Antonio Texas 78229
Virginia Oncology Associates Norfolk Virginia 23502
Northwest Medical Specialists Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03056755, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 12, 2026 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03056755 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →